Healthcare / Drug Manufacturers - Specialty & GenericToronto
$1.00
+0.05 (+5.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 10%
FCF escenarios
weak_data · normalized FCF $17.9M · quality 20.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$373M
P/E
N/A
•EV/EBITDA
8.9x
↓ROE
-88.5%
↓Gross Margin
52.3%
↑Debt/Equity
2.63
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.7%
FCF CAGR
—
FCF margin
4.7%
FCF / Net income
-0.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $260.6M · net income $-86.2M · FCF $12.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $260.6M | $260.6M | $268.1M | $250.5M | $247.8M |
| Net Income | $-86.2M | $-86.2M | $-80.2M | $-95.5M | $-304.0M |
| EBITDA | $58.5M | $58.5M | $54.8M | $43.9M | $-246.5M |
| EPS | -0.29 | -0.29 | -0.28 | -0.34 | -1.35 |
| Gross Margin | 52.3% | 52.3% | 50.7% | 55.1% | 41.0% |
| Operating Margin | 17.1% | 17.1% | 15.4% | 19.9% | -1.6% |
| Net Margin | -33.1% | -33.1% | -29.9% | -38.1% | -122.6% |
| Balance Sheet | |||||
| Debt/Equity | 2.63 | 2.63 | 1.31 | 1.05 | 0.74 |
| Current Ratio | 1.51 | 1.51 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $12.2M | $12.2M | $29.9M | $17.9M | $-68.0M |
| Returns | |||||
| ROE | -88.5% | -88.5% | -45.3% | -39.4% | -95.3% |
| Valuation | |||||
| EV/EBITDA | 8.89 | 8.89 | 8.96 | 21.22 | — |
| P/B | 3.09 | 3.09 | 1.61 | 2.88 | 1.48 |
| Growth & Yield | |||||
| Revenue Growth | -2.8% | -2.8% | 7.0% | 1.1% | — |
| EPS Growth | -3.6% | -3.6% | 17.6% | 74.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+104.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.28 → -0.29
Residual
+104.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.